These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35296205)

  • 1. Neurotoxic and cardiotoxic effects of
    Jeong S; Yoon KS; Lee JM; Jo ES; Kim D; Choi SO
    Drug Chem Toxicol; 2023 May; 46(3):430-440. PubMed ID: 35296205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system.
    Yoon KS; Cha HJ; Choi SO; Lee JM
    Toxicol Lett; 2022 Feb; 355():160-169. PubMed ID: 34843874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
    Qu Y; Fang M; Gao B; Chui RW; Vargas HM
    J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxic effects of [3-[2-(diethylamino)ethyl]-1H-indol-4-yl] acetate and 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-ol.
    Yoon KS; Lee JM; Kim YH; Suh SK; Cha HJ
    Toxicol Lett; 2020 Feb; 319():40-48. PubMed ID: 31706004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
    Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
    Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How toxic is ibogaine?
    Litjens RP; Brunt TM
    Clin Toxicol (Phila); 2016; 54(4):297-302. PubMed ID: 26807959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioridazine Induces Cardiotoxicity via Reactive Oxygen Species-Mediated hERG Channel Deficiency and L-Type Calcium Channel Activation.
    Liu Y; Xu X; Zhang Y; Li M; Guo J; Yan C; Wang F; Li Y; Ding Y; Li B; Fan P
    Oxid Med Cell Longev; 2020; 2020():3690123. PubMed ID: 32064022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development].
    Zhou SB; Wang J; Liu H
    Yao Xue Xue Bao; 2016 Oct; 51(10):1530-9. PubMed ID: 29932317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs.
    Blinova K; Schocken D; Patel D; Daluwatte C; Vicente J; Wu JC; Strauss DG
    Clin Transl Sci; 2019 Nov; 12(6):687-697. PubMed ID: 31328865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological characterization of a small molecule activator on human ether-a-go-go-related gene (hERG) potassium channel.
    Dong X; Liu Y; Niu H; Wang G; Dong L; Zou A; Wang K
    J Pharmacol Sci; 2019 Jul; 140(3):284-290. PubMed ID: 31481348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.
    Meyer T; Boven KH; Günther E; Fejtl M
    Drug Saf; 2004; 27(11):763-72. PubMed ID: 15350150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C.
    Guo J; Zhan S; Lees-Miller JP; Teng G; Duff HJ
    Heart Rhythm; 2005 Aug; 2(8):860-6. PubMed ID: 16051125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential therapeutic value of antioxidants for abnormal prolongation of QT interval and the associated arrhythmias in a rabbit model of diabetes.
    Zhang Y; Sun X; Zhang Y; Wang J; Lu Y; Yang B; Wang Z
    Cell Physiol Biochem; 2011; 28(1):97-102. PubMed ID: 21865852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced hERG block and long QT syndrome.
    Witchel HJ
    Cardiovasc Ther; 2011 Aug; 29(4):251-9. PubMed ID: 20406244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR; Hermans AN; Gallacher DJ
    Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
    Qu Y; Gao B; Fang M; Vargas HM
    J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
    Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
    Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.